Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
KUALA LUMPUR, 14 JULY 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) and US-based foodtech company The Live Green Co. signed a Collaboration Agreement today to explore the use of plant ingredients and technology to replace animal, synthetic and ultra-processed ingredients, to meet consumer demand for more sustainable wellness foods and pharmaceuticals.
● Duopharma Biotech Berhad’s 21st AGM reaffirms the Group’s commitment to maintaining its leading position as an innovative pharmaceutical company in Malaysia and a global leader in the halal sector
● Intensified focus on ESG has made the Group a preferred employer, trusted partner, attractive investment and an increasingly strong brand
Kuala Lumpur, June 15, 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company“) hosted the Third (3rd) Halal Pharmaceuticals Symposium 2022 today, as part of The Company’s continuing quest to spearhead efforts to capture the global halal pharmaceuticals market by facilitating the sharing of best practices, achievements and international collaborations to resolve challenges, advance global standards and jointly shape the industry.
● 1Q 2022 PBT increased by 15% to RM26.65 million compared to previous corresponding quarter
● Revenue gained 12% to RM185.94 million year-on-year
● Improving Malaysian economy, recovery in domestic demand bode well for Duopharma Biotech’s prospects
Kuala Lumpur, February 25 2022 – Uphamol, the leading paracetamol brand from Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) is now the Official Partner for the Malaysian Football League (MFL) in the Analgesic Category for a two-year period from 1 January 2022 to 31 December 2023, as part of a sponsorship agreement with Duopharma Biotech during this period. The sponsorship agreement will cover the Perlawanan Sumbangsih, Liga Super and Piala Malaysia competitions in 2022 and 2023 respectively.
KUALA LUMPUR, 25 FEBRUARY 2022 – Proviton STR, a leading isotonic drink brand from Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has signed on as the new Official Partner for the Malaysian Football League (MFL) in the Isotonic category, as part of a two-year MFL sponsorship by Duopharma Biotech, from 1 January 2022 to 31 December 2023. The sponsorship will cover the Perlawanan Sumbangsih, Liga Super and Piala Malaysia competitions in 2022 and 2023 respectively.
● 4Q revenue grows 8.5% to RM145.44 million compared to previous corresponding quarter
● Second interim dividend of 1.8 sen per share
● New and extended public sector supply contracts, potential tax savings to bolster future earnings
KUALA LUMPUR, 15 DECEMBER 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) officially launched its new Flavettes Nutriskincare range today, further expanding its consumer healthcare portfolio into the health and beauty segment through the established Flavettes brand. In 2021, Flavettes – the No. 1 Adult Vitamin C brand in Malaysia and a market leader in the effervescent Vitamin C segment, targeted the steadily-growing beauty segment with the introduction of Flavettes Nutriskincare variants – building on the popularity of its effervescent Vitamin C products.
Duopharma Biotech Berhad recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax growing 32.1% year-on-year to RM79.71 million, while Profit After Tax rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year.
Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.
Biocon Limited, an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia, valued at over MYR 225 million this year.
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.
Duopharma Biotech Berhad recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year.
Duopharma Biotech Berhad reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024.